# Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China

> **NCT04954131** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Clover Biopharmaceuticals, Inc.** · enrollment: 766 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Candidate Vaccine, SCB-2019
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04954131
- **Lead sponsor:** Zhejiang Clover Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-10
- **Primary completion:** 2021-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 766 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04954131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04954131, "Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04954131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*